Table 2 Baseline patient characteristics comparing patients who progressed to RA with those who did not in ANSWER validation cohort
Baseline characteristics | Overall (n = 140) | RA (n = 45) | Non-RA (n = 95) | p-value |
|---|---|---|---|---|
age (median, [Q1-Q3]) | 62.5 [48.0–72.0] | 54.0 [46.0–70.0] | 64.0 [50.0–73.0] | 0.112 |
sex (female%) | 67.9% | 75.6% | 62.4% | 0.251 |
BMI (median, [Q1-Q3]) | 21.7 [19.8–24.7] | 21.6 [19.8–24.8] | 21.9 [19.8–24.2] | 0.617 |
Family history of RA (positive %) | 14.3% | 17.8% | 12.6% | 0.580 |
Smoking (current or previous %) | 67.2% | 65.0% | 68.40% | 0.430 |
CRP (median, [Q1-Q3]) | 2.7 [0.050–14.6] | 9.4 [1.0-31.4] | 2.0 [0.4–0.96] | 0.011 |
ESR_1h (median, [Q1-Q3]) | 18.5 [8.0–37.0] | 26.0 [12.0-44.3] | 15.0 [5.0–34.0] | 0.024 |
RF (median, [Q1-Q3]) | 5 [5–8] | 5 [4–7] | 5 [5–8] |  |
ACPA (median, [Q1-Q3]) | 0.6 [0.6–0.6] | 0.6 [0.6–0.6] | 0.6 [0.6–0.6] |  |
MMP-3 (median, [Q1-Q3]) | 75.7 [40.3-134.7] | 95.1 [44.5-189.9] | 56.9 [39.7–118.0] | 0.030 |
PhGA (median, [Q1-Q3]) | 20.0 [10.5–36.5] | 30.0 [12.0–50.0] | 18.0 [10.0–30.0] | 0.040 |
PtGA (median, [Q1-Q3]) | 50.0 [29.0-67.5] | 50.0 [32.0–68.0] | 50.0 [27.0–66.0] | 0.371 |
TJC28 (median, [Q1-Q3]) | 2 [1–5] | 3 [1–5] | 2 [1–5] | 0.837 |
SJC28 (median, [Q1-Q3]) | 1 [0–3] | 1.0 [0–4.0] | 1 [0–3] | 0.943 |
CDAI (median, [Q1-Q3]) | 12.0 [8.35–15.85] | 11.8 [8.68–17.6] | 12.0 [8.35–15.35] | 0.578 |
HAQ-DI (median, [Q1-Q3]) | 0.5 [0.13–0.88] | 0.63 [0.25–1.44] | 0.38 [0.13–0.75] | 0.027 |
Days to diagnosis (median, [Q1-Q3]) |  | 92 [36–273] |  |  |